Share on StockTwits

ANI Pharmaceuticals (NASDAQ:ANIP) Director Ross J. Mangano acquired 2,000 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average price of $30.38 per share, with a total value of $60,760.00. Following the completion of the transaction, the director now directly owns 23,914 shares in the company, valued at approximately $726,507. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on ANIP shares. Analysts at Roth Capital raised their price target on shares of ANI Pharmaceuticals from $36.00 to $38.00 in a research note on Tuesday. Separately, analysts at Zacks downgraded shares of ANI Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, April 22nd. They now have a $31.60 price target on the stock. Finally, analysts at Zacks upgraded shares of ANI Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Tuesday, March 11th. They now have a $38.50 price target on the stock.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded down 0.42% on Wednesday, hitting $31.14. The stock had a trading volume of 229,739 shares. ANI Pharmaceuticals has a 52 week low of $4.80 and a 52 week high of $38.74. The stock has a 50-day moving average of $30.00 and a 200-day moving average of $22.33. The company’s market cap is $300.2 million.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Monday, May 5th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $11.40 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. The company’s revenue for the quarter was up 94.6% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals will post $1.74 earnings per share for the current fiscal year.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.